High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy

Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is effective in patients with EGFR-TKI sensitizing and T790M resistant mutation-positive advanced non-small cell lung cancer (NSCLC) [1.Janne P.A. Yang J.C. Kim D.W. et al.AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.N Engl J Med. 2015; 372: 1689-1699Crossref PubMed Scopus (1627) Google Scholar,2.Yang J. Ramalingam S.S....